INBX - Inhibrx Biosciences Tezkor likvidlik koeffitsiyenti

Inhibrx Biosciences (INBX) kompaniyasining istiqbollari noyob patologiyalar uchun dori vositalarini sinovdan o'tkazish natijalari va yirik hamkorlarning qo'llab-quvvatlashiga bog'liq. GURU.Markets platformasidagi ushbu narxlar grafigi aktivning dinamikasini aks ettiradi, bunda joriy ko'rsatkich 5.15 ni tashkil etadi. Protein muhandislarining barqaror shtati ishlanmalarning ishonchliligini ta'minlaydi, pul oqimi esa INBRX-101 loyihasi uchun Sanofi kompaniyasidan keladigan to'lovlarga tayanadi.

Inhibrx Corp (INBX) Tezkor likvidlik: 04.07.2022 - 29.10.2026 davri uchun

Inhibrx Biosciences kompaniyasining tahliliy kesimlari

- bozor qiymati va tahlilchilarning maqsadli prognozi:

Narx grafigi Inhibrx Biosciences Inc|INBX - Adolatli qiymat konsensusi

- bozor kapitallashuvi statistikasi:

Bozor kapitallashuvi Inhibrx Biosciences Inc|INBX - Korxona qiymati

- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:

Bitta aksiya uchun sof aktivlar Inhibrx Biosciences|INBX - Kompaniyaning balans qiymati|Kapitallashuvning sof aktivlarga nisbati inhibrx.com|INBX - Aktivlarning umumiy qiymati

- qarz va likvidlik bo'yicha ma'lumotlar:

Qarzning xususiy kapitalga nisbati Inhibrx Biosciences|INBX - Uzoq muddatli majburiyatlarning kapitalga nisbati|Qisqa muddatli qarzning o'z kapitaliga nisbati Inhibrx Biosciences, Inc.|INBX - Kompaniyaning jamlangan qarzi|Balans kapitallashuviga qarzlar Inhibrx Biosciences Inc|INBX - Kompaniyaning uzoq muddatli majburiyatlari|Kompaniyaning qisqa muddatli qarzi Inhibrx Biosciences|Tezkor likvidlik inhibrx.com

- foyda va bozor multiplikatorlari tafsilotlari:

INBX - Kompaniyaning sof foydasi

Kompaniyaning jamlanma tahlili:Inhibrx Biosciences Inc - INBX

Inhibrx Biosciences, Inc. ishlab chiqargan mahsulot

Tezkor koeffitsient kompaniyaning past likvidlikka ega zaxiralarni butunlay chiqarib tashlagan holda, o'zining eng likvid aktivlari yordamida qisqa muddatli qarzlarni to'lash qobiliyatini o'lchaydi. Absolyut likvidlik koeffitsientini tahlil qilish orqali investor haqiqiy to'lov qobiliyatini qog'ozdagi kapitaldan ajratadi. Ushbu grafik yuqori xarajatlar fonida Inhibrx Biosciences (INBX) moliyaviy barqarorligini aks ettiradi. Bu operatsion faoliyatga zarar yetkazmagan holda laboratoriyalarning ekologik modernizatsiyasini moliyalashtirish va filtratsiya tizimlarini joriy qilish uchun juda muhimdir.

Asosiy raqobatchilar

Incyte Corp. (INCY) - Tezkor likvidlik|HUTCHMED Corp - Oraliq qoplash koeffitsiyenti|NUVB (Nuvation Bio Inc.) - Tezkor likvidlik koeffitsiyenti|Tezkor likvidlik koeffitsiyenti dayonebio.com|Tezkor likvidlik Monopar Therapeutics Inc. (MNPR)|Tezkor likvidlik IMAB (i-mabbiopharma.com)|Fennec Pharmaceuticals Inc - Tezkor likvidlik ko‘rsatkichi|Oraliq qoplash koeffitsiyenti HRTX|NVCT - Tezkor likvidlik|Shoshilinch likvidlik Coherus BioSciences Inc.|Corbus Pharmaceuticals Holdings (CRBP) - Tezkor likvidlik|Shoshilinch likvidlik koeffitsiyenti CRDF|BYSI (BeyondSpring Pharma) - Tezkor likvidlik koeffitsiyenti|Tezkor likvidlik ko‘rsatkichi BioAtla Corp (BCAB)|Tezkor likvidlik Lixte Biotechnology (LIXT)|CTXR - Shoshilinch likvidlik|Tezkor likvidlik Cellectar Biosciences, Inc. CLRB|BioLineRx Ltd - Tezkor likvidlik|CANF - Tezkor likvidlik|Shoshilinch likvidlik Aprea Therapeutics|KZIA: Tezkor likvidlik koeffitsiyenti|Kritik likvidlik Silexion Therapeutics SLXN|Tezkor likvidlik ko‘rsatkichi NCNA|Shoshilinch likvidlik Chimerix Inc. CMRX|Tezkor likvidlik ko‘rsatkichi CYCC (Cyclacel Pharmaceuticals Inc.)|GTHX (g1therapeutics.com) - Oraliq qoplash koeffitsiyenti|Kronos Bio, Inc. - Tezkor likvidlik ko‘rsatkichi|Oraliq likvidlik koeffitsiyenti KTRA (kintara.com)|Oncternal Therapeutics, Inc. - Tezkor likvidlik koeffitsiyenti|Oraliq qoplash koeffitsiyenti PRTG (Portage Biotech Inc)